Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer

Welslau, Manfred, Diéras, Veronique, Sohn, Joo‐Hyuk, Hurvitz, Sara A., Lalla, Deepa, Fang, Liang, Althaus, Betsy, Guardino, Ellie +1 more·2014·Cancer
DOI 10.1002/cncr.28465

Cited by (126)

Items 101–126 of 126

  1. Impact of tumor cellularity on the HER2 amplification assay by OncoScan™ in breast cancer
    Ako Ohara, Yasuto Naoi, Masafumi Shimoda, Tomonori Tanei, Naofumi Kagara, Tomohiro Miyake, Yoshiaki Sota, Seung Jin Kim, Kenzo Shimazu, Shinzaburo Noguchi · 2021 · Breast Cancer
  2. Meta-analysis of quality of life in patients with cancer treated with antibody-drug conjugates in randomized controlled trials
    Tianlei Qiu, Guoshuang Shen, Yuanfang Xin, Jinming Li, Yonghui Zheng, Zijun Zhu, Cheng-Rong Zhang, Yuyao Tang, Miaozhou Wang, Zhen Liu et al. · 2023 · Future Oncology
  3. Trastuzumab Biosimilar (HLX02), Pertuzumab Plus Chemotherapy in Patients with HER2-Positive Metastatic Breast Cancer after Progression of Trastuzumab: A Prospective, Phase II Study
    Ruyan Zhang, Xiaoran Liu, Guohong Song, Yan Zhang, Huiping Li · 2023 · Cancer Research and Treatment
  4. HER2-Positive Metastatic Breast Cancer: Second-Line Treatment
    Ricardo H. Álvarez · 2013
  5. Resposta prolongada durante 43 ciclos de trastuzumabe entansina (T-DM1) em paciente com câncer de mama metastático com superexpressão de HER2: relato de caso
    Larissa Andressa Orsolini, Ruffo Freitas‐Júnior, Luiz Fernando Jubé Ribeiro, Geraldo Silva Queiroz, Tâmara Naves Moraes · 2016 · Revista Brasileira de Mastologia
  6. A modern paradigm for treating HER2-positive advanced breast cancer: Dual HER2 blockade and antibody-drug conjugates
    Konstantin Evgen’evich Borisov, Dina Sakaeva · 2015 · P A Herzen Journal of Oncology
  7. Tyrosine Kinase Inhibitors
    Burcu Çakar, Erdem Göker · 2016 · Springer eBooks
  8. 11. Breast Treatment (1) Surgical Treatment and Chemotherapy: Now and Future
    Masaru Kuranami · 2013 · Japanese Journal of Radiological Technology
  9. Erhaltungstherapie bei metastasiertem Mammakarzinom
    Viktoria Aivazova-Fuchs, K Friese · 2017 · Der Gynäkologe
  10. Lapatinib
    Giuseppe Tridente · 2017 · Elsevier eBooks
  11. Clinical Diagnostic Imaging
    Masayuki Yokoyama, Kouichi Shiraishi · 2018 · Springer eBooks
  12. Zielgerichtete Therapie des Mammakarzinoms
    Katharina Seiffert, Barbara Schmalfeldt, Volkmar Müller · 2018 · Senologie - Zeitschrift für Mammadiagnostik und -therapie
  13. Efficacy of second-line treatment with capecitabine and lapatinib in HER2-positive mammary neoplasia, with encephalic metastasis, after first-line therapy with dual anti-HER2 block
    Tea Zeppola · 2018 · AboutOpen
  14. The Synergistic Antitumor Effect of Combined Anti-Human Epidermal Growth Factor Receptor 2 Antibody and Gamma Interferon Therapy on Antibody-resistant Breast Cancer Cells
    Toshihiko Gocho, Hiromichi Tsuchiya, Shotaro Kamijo, Yoshitaka Yamazaki, Yui Akita, Akiko Sasaki, Yuji Kiuchi · 2019 · The Showa University Journal of Medical Sciences
  15. Multilineal treatment strategy of HER2-positive metastatic breast cancer (clinical case)
    Айнур Фанутович Насретдинов, А. В. Пушкарев, Oleg Nikolaevich Lipatov, Н. И. Султанбаева, Шамиль Исмагилович Мусин, Константин Викторович Меньшиков, Адель Альбертович Измайлов, В. А. Пушкарев, М Г Галеев, R. R. Muginov et al. · 2021 · Tumors of female reproductive system
  16. A narrative review of human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugates in the treatment of breast cancer
    Qun Li, Ye Guo, Fengjuan Lin, Lingjun Li, Xiaoxiao Ge, Wei Zhao, Jin Li · 2021 · Translational Breast Cancer Research
  17. EV (Extracellular Vesicle)‐associated miRNAs as Biomarkers of Toxicity
    Ryuichi Ono, Yusuke Yoshioka, Yusuke Furukawa, Mie Naruse, Makiko Kuwagata, Takahiro Ochiya, Satoshi Kitajima, Yoko Hirabayashi · 2022
  18. HER2-positive metastatic breast cancer: second-line treatment
    Ricardo H. Álvarez · 2016 · Springer eBooks
  19. Treatment of HER2-Overexpressing Metastatic Breast Cancer
    Adnan Aydıner · 2019 · Springer eBooks
  20. Nanotechnology in the development of small and large molecule tyrosine kinase inhibitors and immunotherapy for the treatment of HER2-positive breast cancer.
    Victor Ejigah, Bharathi Mandala, Emmanuel O. Akala · 2022 · PubMed
  21. Efficacy of trastuzumab in treatment of disseminated HER2-positive ductal adenocarcinoma of the submandibular gland (a case report)
    Ali Muradovich Mudunov, I. М. Gelfand, О. D. Ryzhova, М. Б. Пак, A. S. Tarakanova, I. O. Tarakanov, A. S. Morozova, H. Chen · 2025 · Head and neck tumors (HNT)
  22. Additional file 1 of Factors associated with overall survival in breast cancer patients with leptomeningeal disease (LMD): a single institutional retrospective review
    Wallace, Gerald, Ronak Kundalia, Ethan J. Vallebuona, Biwei Cao, Kim, Youngchul, Forsyth, Peter, Aixa Elena Soyano, Inna Smalley, Yolanda Piña · 2024 · Figshare
  23. Additional file 2 of Factors associated with overall survival in breast cancer patients with leptomeningeal disease (LMD): a single institutional retrospective review
    Wallace, Gerald, Ronak Kundalia, Ethan J. Vallebuona, Biwei Cao, Kim, Youngchul, Forsyth, Peter, Aixa Elena Soyano, Inna Smalley, Yolanda Piña · 2024 · Figshare
  24. Commercialized ADCs: A Market Snapshot for Exemplification
    Ajmeeta Sangtani, Valentina Vozella · 2026 · AAPS advances in the pharmaceutical sciences series
  25. La souris humanisée : modèle d'étude de l'immunothérapie anti-cancer
    Philippe De La Rochère · 2018
  26. Real-world patient-reported outcome comparing antibody–drug conjugates and conventional chemotherapy in metastatic breast cancer
    Manuela Milani, Francesco Riccetelli, Carla Strina, Marzia Alberio, Valeria Cervoni, Nicoletta Ziglioli, Donatella Caffi, Francesca Ferré, Massimo Di Maïo, Gabriella Pravettoni et al. · 2026 · The Oncologist